Invasive Breast Cancer Clinical Trial
Official title:
Evaluation of the RESTART Survival Programme
The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme.
Prospective longitudinal, single-centre, non-randomised study for patients who have completed acute treatment (surgery, radiotherapy, chemotherapy) for localised breast cancer within the last 3 months. In this project, investigtors are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme. The primary objective is to assess satisfaction with participation in the Restart programme and its various components. Evaluation criteria associated with the primary objective: Measurement of overall satisfaction and of the various components of the RESTART programme (Likert scale and open questions) - Evaluation criteria associated with the secondary objective: To measure before starting the RESTART programme and 1 and 12 months after the end of the programme: - Patients' Quality of Life (QoL) (using the EORTC30 and BR23 questionnaires for breast cancer) - Health literacy (via the HLQ questionnaire) - Professional status - Patients' physical activity level via the Global Physical Activity Questionnaire (GPAQ) - Psychological distress, anxiety and depressive symptoms via the Generalized Anxiety Disorder - 7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) questionnaires - Fatigue (via the NRS) - Patient sleep quality using the Pittsburgh Sleep Quality Index (PSQI) To measure the rate of participation in the programme via the proportion of patients who participated in relation to the number of patients operated on for breast cancer located in Bordet during the same period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03595592 -
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05383196 -
Onvansertib + Paclitaxel In TNBC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06158217 -
Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer
|
||
| Active, not recruiting |
NCT04448886 -
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC
|
Phase 2 | |
| Completed |
NCT02773784 -
Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.
|
||
| Recruiting |
NCT01509781 -
Suction Drain Versus the Use of Adaptive Skin Sutures After Mastectomy ± Axillary Lymphadenectomy; a Prospective Randomised Study
|
Phase 3 | |
| Completed |
NCT04478669 -
Digital Breast Tomosynthesis (DBT) to Improve Assessment of Resection Margins in Invasive Breast Cancer
|
||
| Recruiting |
NCT04553770 -
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT04677816 -
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
|
Phase 2 | |
| Terminated |
NCT01934335 -
Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer
|
Phase 2 | |
| Completed |
NCT00507611 -
Axillary Lymph Node Status After Completion of Preoperative Neoadjuvant Systemic Chemotherapy in Patients
|
N/A | |
| Completed |
NCT00581750 -
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
|
||
| Completed |
NCT03304171 -
Overall Diet Quality and Breast Cancer Risk
|
N/A | |
| Completed |
NCT03709186 -
Radiomic Markers for Breast Cancer Metastasis and Treatment Response Using MRI
|
||
| Terminated |
NCT03361800 -
Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
|
Early Phase 1 | |
| Recruiting |
NCT04648904 -
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
|
Early Phase 1 | |
| Recruiting |
NCT06328465 -
fREEDOM: REsonance for Early Detection Of Breast Cancer Metastases
|
N/A | |
| Active, not recruiting |
NCT03109522 -
Axillary Reverse Mapping (ARM) Technique
|
N/A | |
| Recruiting |
NCT03987555 -
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
|
||
| Recruiting |
NCT03497702 -
Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer
|
Phase 2 |